Los puntos clave no están disponibles para este artículo en este momento.
In recent years as a result of the SARS-CoV-2 infection antiviral drugs have received more attention and many potential drug molecules are currently under investigation to end the epidemic.Molnupiravir, a prodrug is one of the assuring candidates for SARS-CoV-2.Therefore, the current research work was having the aim to investigate the easy, defined, sensitive and robust avenue as a liquid chromatography for estimation of molnupiravir from pure blend and its dosage form.The reversed-phase chromatographic appropriate and efficient separation for molnupiravir has been attained with Hypersil BDS C18 column along with Water: acetonitrile (70: 30 % v/v) solvent system.The determination was performed at 30 oC at 1 mL/min rate for flow of solvent system through column.The eluents of column were monitored using Photodiode Array detector (PDA) at 235 nm.The investigated reversed-phase chromatographic appropriate and efficient separation for molnupiravir revealed admirable retention time i.e. 4.009 min.The developed investigation molnupiravir was show linear response in the concentration range of 10-50 µg/mL with better coefficients of determination was above than (r 2 0.999).The estimable liquid chromatography was successfully validated as per to ICH guidelines and all method validation parameters of estimable in compliance with ICH guidelines (Technical Requirements for Pharmaceuticals for Human use standards).The developed liquid chromatographic avenues were easy, defined, sensitive, robust and rugged and have admirable potential to estimate molnupiravir from pure blend and its dosage form.Thus, the projected admirable reversed-phase chromatographic method has high prospect to adopt in the pharmaceutical industry.
Ambhore et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: